Skip to content

NASDAQ · mid · thesis board

BEAM Beam Therapeutics

Base editing (BEAM-101 / BEAM-302)

View race

Thesis

Editorial summary — not a primary filing

Base editing across SCD and in vivo rare disease; platform optionality is the story.

Next gate

2026-12-10EstimatedPh2 readout

BEAM-101 update

119 days · Estimated: Estimated window

Survive-to-Event

ok

Cash covers the next gate with ~16 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~602d)100%
Days to gate (119d)20%
Show math

$950M cash ÷ $48M/mo burn ≈ 602 days. Source: curated SEC quarter figures.

Cash $950M as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved
Secondary assets (1)
  • BEAM-302 AATD · Ph1 · gene-editing-rare

Rivals in this race

Open race →
CRSPApprovedokBLUEApprovedokEDITPh2ok

Risks

  • Platform breadth vs focus
  • Clinical timelines
  • Competition
  • Delivery

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT05456880as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01